Could These 9 Drugs Gain FDA Approval in the Age of Trump?
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet'sAdam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era.
Alkermes
CytRX
Dynavax Technologies
Intra-Cellular Therapies
Scroll to Continue
TheStreet Recommends
Novan
Portola Pharmaceuticals
PTC Therapeutics
Rigel Pharmaceuticals
TG Therapeutics
READ THE FULL STORY HERE:
These 'Gnarly 9' Biotechs Will Test the FDA's Mettle
This article was written by a staff member of TheStreet.
